塞拉万斯生物制药

最新新闻

• 公司公告
  Theravance Biopharma: Theravance Biopharma, Inc. - Partial Self Tender Offer Option Symbol: TBPH
  OCC · 2022/10/4
• 评级变动
  B. Riley Securities Maintains Theravance Biopharma(TBPH.US) With Hold Rating, Raises Target Price to $17
  \u5e02\u573a\u8d44\u8baf · 2026/4/7
• 公司公告
  Theravance Biopharma(Delisted): Theravance Biopharma, Inc. - Cash Settlement/Acceleration of Expirations Option Symbol: TBPH
  OCC · 2026/9/24
• 评级变动
  TD Cowen Maintains Theravance Biopharma(TBPH.US) With Hold Rating, Raises Target Price to $15
  \u5e02\u573a\u8d44\u8baf · 2026/3/23
• 评级变动
  BTIG Maintains Theravance Biopharma(TBPH.US) With Buy Rating, Maintains Target Price $21
  \u5e02\u573a\u8d44\u8baf · 2026/5/8
• 评级变动
  B. Riley Securities Downgrades Theravance Biopharma(TBPH.US) to Hold Rating, Cuts Target Price to $14
  \u5e02\u573a\u8d44\u8baf · 2026/3/4
• 公司公告
  Theravance Biopharma: Theravance Biopharma, Inc. - Anticipated Cash Settlement Option Symbol: TBPH
  OCC · 2026/8/29
• 评级变动
  TD Cowen Maintains Theravance Biopharma(TBPH.US) With Hold Rating, Maintains Target Price $15
  \u5e02\u573a\u8d44\u8baf · 2026/3/23
• 评级变动
  JonesTrading Maintains Theravance Biopharma(TBPH.US) With Buy Rating, Raises Target Price to $18
  \u5e02\u573a\u8d44\u8baf · 2026/3/26
• 评级变动
  JonesTrading Maintains Theravance Biopharma(TBPH.US) With Buy Rating, Raises Target Price to $19
  \u5e02\u573a\u8d44\u8baf · 2026/5/28
• 评级变动
  Analysts' Opinions Are Mixed on These Healthcare Stocks: Rocket Pharmaceuticals (RCKT), Fractyl Health, Inc. (GUTS) and Theravance Biopharma (TBPH)
  TipRanks · 2026/8/11
• BTIG Downgrades Theravance Biopharma(TBPH.US) to Hold Rating
  \u5e02\u573a\u8d44\u8baf · 2026/6/29
• H.C. Wainwright Downgrades Theravance Biopharma(TBPH.US) to Hold Rating, Raises Target Price to $17
  \u5e02\u573a\u8d44\u8baf · 2026/7/7
• 公司公告
  Theravance Biopharma(Delisted): Theravance Biopharma, Inc.- Broker-To-Broker Settlement/Exercise Considerations Option Symbol: TBPH
  OCC · 2026/9/24
• Theravance Biopharma(TBPH.US) 10% Shareholder Sells US$5.79 Million in Common Stock
  \u5e02\u573a\u8d44\u8baf · 2026/7/2
• 评级变动
  JonesTrading Maintains Theravance Biopharma(TBPH.US) With Buy Rating, Cuts Target Price to $17
  \u5e02\u573a\u8d44\u8baf · 2026/3/5
• 评级变动
  H.C. Wainwright Maintains Theravance Biopharma(TBPH.US) With Buy Rating, Cuts Target Price to $15
  \u5e02\u573a\u8d44\u8baf · 2026/3/5
• H.C. Wainwright Maintains Theravance Biopharma(TBPH.US) With Hold Rating, Maintains Target Price $17
  \u5e02\u573a\u8d44\u8baf · 2026/8/11
• Analysts Offer Insights on Healthcare Companies: Evommune, Inc. (EVMN) and Theravance Biopharma (TBPH)
  TipRanks · 2026/6/29
• 评级变动
  Oppenheimer Downgrades Theravance Biopharma(TBPH.US) to Hold Rating, Cuts Target Price to $13.67
  \u5e02\u573a\u8d44\u8baf · 2026/3/6

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。